DOCSLIB.ORG
  • Sign Up
  • Log In
  • Upload
  • Sign Up
  • Log In
  • Upload
  • Home
  • »  Tags
  • »  Reproterol

Reproterol

  • Validation of New Analytical Methodology for Determining Fenoterolhydrobromide by HPLC: Application in Pharmaceutical Products

    Validation of New Analytical Methodology for Determining Fenoterolhydrobromide by HPLC: Application in Pharmaceutical Products

  • Ep 2560611 B1

    Ep 2560611 B1

  • ADD/ADHD: Strattera • Allergy/Anti-Inflammatories

    ADD/ADHD: Strattera • Allergy/Anti-Inflammatories

  • Ep 2626065 A1

    Ep 2626065 A1

  • 5 August 2004 Version

    5 August 2004 Version

  • ATC/DDD Classification

    ATC/DDD Classification

  • 100 Storage Condition=50 C/Ambrh

    100 Storage Condition=50 C/Ambrh

  • WO 2014/141069 Al 18 September 2014 (18.09.2014) P O P C T

    WO 2014/141069 Al 18 September 2014 (18.09.2014) P O P C T

  • Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1

    Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1

  • (12) Patent Application Publication (10) Pub. No.: US 2009/0047336A1 Yang Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2009/0047336A1 Yang Et Al

  • Management of Asthma in Athletes Michael G

    Management of Asthma in Athletes Michael G

  • Short-Acting Inhaled B2-Agonists: Why, Whom, What, How?

    Short-Acting Inhaled B2-Agonists: Why, Whom, What, How?

  • (12) Patent Application Publication (10) Pub. No.: US 2014/0302147 A1 HARTMAN Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2014/0302147 A1 HARTMAN Et Al

  • Salmeterol Xinafoate

    Salmeterol Xinafoate

  • Supplementary Material A: RECORD Statement

    Supplementary Material A: RECORD Statement

  • Study Protocol and Statistical Analysis Plan

    Study Protocol and Statistical Analysis Plan

  • May 2018 Comparator Descriptions and Specifications

    May 2018 Comparator Descriptions and Specifications

  • Bronchospasmin® 1 Ml Injektionslösung

    Bronchospasmin® 1 Ml Injektionslösung

Top View
  • (12) United States Patent (10) Patent No.: US 8.426,475 B2 Weidner Et Al
  • 2021 Equine Prohibited Substances List
  • Global Strategy for Asthma Management and Prevention Online Appendix
  • Section B Changed Classes/Guidelines Final Version Date of Issue
  • Supplementary File
  • Benefit Assessment of Medicinal Products with New Active
  • Inhalation Composition Containing Aclidinium for Treatment of Asthma and Chronic Obstructive Pulmonary Disease
  • Amineptine, Amiphenazole, Amphetamines, Bromantan, Caffeine
  • Statistical Analysis Plan
  • Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
  • Shelley 2004 Cardiovasc B2ag
  • Study Protocols
  • TUE Physician Guidelines ASTHMA 1. Medical Condition
  • Justification
  • (12) United States Patent (Io) Patent No.: US 9,526,824 B2 Ferrari Et Al
  • Inhalation Composition Containing Aclidinium for Treatment of Asthma and Chronic Obstructive Pulmonary Disease
  • NVA237 / Glycopyrronium Bromide Multinational, Multi-Database Cohort
  • Customs Tariff - Schedule Xxi - 1


© 2024 Docslib.org    Feedback